Download MendeleyTricyclic-Carbocyclic ROR gamma t Inverse Agonists-Discovery of BMS-986313.
Yang, M.G., Beaudoin-Bertrand, M., Xiao, Z., Marcoux, D., Weigelt, C.A., Yip, S., Wu, D.R., Ruzanov, M., Sack, J.S., Wang, J., Yarde, M., Li, S., Shuster, D.J., Xie, J.H., Sherry, T., Obermeier, M.T., Fura, A., Stefanski, K., Cornelius, G., Khandelwal, P., Karmakar, A., Basha, M., Babu, V., Gupta, A.K., Mathur, A., Salter-Cid, L., Denton, R., Zhao, Q., Dhar, T.G.M.(2021) J Med Chem 64: 2714-2724
- PubMed: 33591748
- DOI: https://doi.org/10.1021/acs.jmedchem.0c01992
- Primary Citation of Related Structures:
7KQJ - PubMed Abstract:
SAR efforts directed at identifying RORγt inverse agonists structurally different from our clinical compound 1 (BMS-986251) led to tricyclic-carbocyclic analogues represented by 3 - 7 and culminated in the identification of 3d (BMS-986313), with structural differences distinct from 1 . The X-ray co-crystal structure of 3d with the ligand binding domain of RORγt revealed several key interactions, which are different from 1 . The in vitro and in vivo PK profiles of 3d are described. In addition, we demonstrate robust efficacy of 3d in two preclinical models of psoriasis-the IMQ-induced skin lesion model and the IL-23-induced acanthosis model. The efficacy seen with 3d in these models is comparable to the results observed with 1 .
Organizational Affiliation:
Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
